Herein, we demonstrate an effective CAR-T cell treatment for recurrent and malignant CD30-positive peripheral T-cell lymphomas (PTCL) has been demonstrated. This evidence concerns the gene TNFRSF8 and peripheral T-cell lymphoma, not otherwise specified.